Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden
Carl-Henrik
Heldin
Signaling, Tumor biology
Bio

I have been Director of the Ludwig Institute in Uppsala since 1986. I'm also a professor of Molecular Cell Biology at Uppsala University.

I was born in 1952, and obtained a PhD in Medical and Pphysiological Chemistry in 1980 at the University of Uppsala, where I continued to work until 1985 in a position sponsored by the Swedish Cancer Society.

I am an elected member of the European Molecular Biology Organization (1989), Royal Swedish Academy of Sciences (1991), Royal Scientific Society (Uppsala; 1995), Academia Europea (1999), Japanese Association for Cancer Research (2002), Finnish Scientific Society (2006), ScanBalt Academy (2006), Hellenic Biochemical Society (2007), Norwegian Academy of Sciences and Letters (2009) and European Academy of Cancer Sciences (2009). I am Doctor honoris causa at the universities of Patras (2009), Helsinki (2010), Turku (2011) and Heidelberg (2011).

I have served on the Scientific Advisory Boards for several companies and academic institutions, including the European Molecular Biology Organization, Heidelberg; the German Cancer Center, Heidelberg; and the Max Planck Institute for Biochemistry, Martinsried; and now serve on the Scientific Advisory Boards for the European Institute for Oncology, Milan; Biotechnology Center, Oslo; Center for Molecular Medicine, Vienna; and the Finnish Institute for Molecular Medicine, Helsinki. I have served on the Board of the Swedish Research Council, and am  Vice President of the European Research Council and the Chair of the Board of the Nobel Foundation. I also serve as Associate Editor for Molecular Biology of the Cell, Genes to Cells and Growth Factors.

I have published 394 research articles and 195 review articles, and have 26 approved patents. My work has been cited  more than 55,000 times. My H‑index is 128.


Achievements

Prix Antoine Lacasagne, 1989

EMBO Medal, 1992

K. Fernström’s Large medical prize, 1993

Meyenburg Prize, 1999

Pezcollar‑AACR Prize, 2002

Honorary medal of the Signal Transduction Society, 2012

Read More

Carl-Henrik Heldin lab

My research focuses on the mechanisms whereby growth factors, in particular PDGF and TGFß, activate their receptors and control cell growth, migration, apoptosis and differentiation, and how perturbations of signaling pathways promote tumor progression. An aim is to explore the usefulness of signal transduction inhibitors for tumor treatment.

Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden
Carl-Henrik
Heldin
Signaling, Tumor biology
Bio

I have been Director of the Ludwig Institute in Uppsala since 1986. I'm also a professor of Molecular Cell Biology at Uppsala University.

I was born in 1952, and obtained a PhD in Medical and Pphysiological Chemistry in 1980 at the University of Uppsala, where I continued to work until 1985 in a position sponsored by the Swedish Cancer Society.

I am an elected member of the European Molecular Biology Organization (1989), Royal Swedish Academy of Sciences (1991), Royal Scientific Society (Uppsala; 1995), Academia Europea (1999), Japanese Association for Cancer Research (2002), Finnish Scientific Society (2006), ScanBalt Academy (2006), Hellenic Biochemical Society (2007), Norwegian Academy of Sciences and Letters (2009) and European Academy of Cancer Sciences (2009). I am Doctor honoris causa at the universities of Patras (2009), Helsinki (2010), Turku (2011) and Heidelberg (2011).

I have served on the Scientific Advisory Boards for several companies and academic institutions, including the European Molecular Biology Organization, Heidelberg; the German Cancer Center, Heidelberg; and the Max Planck Institute for Biochemistry, Martinsried; and now serve on the Scientific Advisory Boards for the European Institute for Oncology, Milan; Biotechnology Center, Oslo; Center for Molecular Medicine, Vienna; and the Finnish Institute for Molecular Medicine, Helsinki. I have served on the Board of the Swedish Research Council, and am  Vice President of the European Research Council and the Chair of the Board of the Nobel Foundation. I also serve as Associate Editor for Molecular Biology of the Cell, Genes to Cells and Growth Factors.

I have published 394 research articles and 195 review articles, and have 26 approved patents. My work has been cited  more than 55,000 times. My H‑index is 128.


Achievements

Prix Antoine Lacasagne, 1989

EMBO Medal, 1992

K. Fernström’s Large medical prize, 1993

Meyenburg Prize, 1999

Pezcollar‑AACR Prize, 2002

Honorary medal of the Signal Transduction Society, 2012

Read More

RESEARCH AREAS

I am investigating the mechanisms of signal transduction by growth regulatory factors, as well as their normal function and role in disease. In particular, we study platelet-derived growth factor (PDGF), a major mitogen for connective tissue cells, and transforming growth factor β (TGFβ), which inhibits the growth of most cell types. We try to elucidate the mechanisms that activate PDGF and TGFβ receptors and the intracellular signaling pathways these receptors initiate, and how they control cell growth, migration, survival and differentiation. We are also exploring the mechanisms that terminate signaling. Αn important goal is to explore the possible clinical utility of signal transduction antagonists.

PUBLICATIONS

Lennartsson, J., Wardega, P., Ma, H., Pelka, K., Engström, U., Hellberg, C., and Heldin, C.-H. (2013). The Fer tyrosine kinase is important for platelet-derived growth factor BB-induced Stat3 phosphorylation and colony formation in soft agar. J. Biol. Chem. (in press).

Heldin, C.-H., Vanlandewijck, M., and Moustakas, A. (2012). Regulation of EMT by TGFβ in cancer. FEBS Lett. 586, 1959-1970.

Mu, Y., Sundar, R., Thakur, N., Ekman, M., Gudey, S.K., Yakymovych, M., Hermansson, A., Dimitriou, H., Bengoechea-Alonso, M.T., Ericsson, J., Heldin, C.-H., and Landström, M. (2011). TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer. Nature Communications 2, 330.

Lönn, P., van der Heide, L., Dahl, M., Hellman, U., Heldin, C.-H., and Moustakas, A. (2010). PARP-1 attenuates Smad-mediated transcription. Mol. Cell 40, 521-532.

Sorrentino, A., Thakur, N., Grimsby, S., Marcusson, A., von Bulow, V., Schuster, N., Zhang, S., Heldin, C.-H., and Landström, M. (2008). The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nature Cell Biol. 10, 1199-1207.